Navigation Links
Brain Tumor Vaccine Shows Promise in Early Trial
Date:4/17/2012

By Maureen Salamon
HealthDay Reporter

TUESDAY, April 17 (HealthDay News) -- A vaccine made from brain cancer patients' own tumor cells led to a nearly 50 percent improvement in survival times for those stricken with glioblastoma multiforme, the same malignancy that claimed the life of U.S. Sen. Edward Kennedy, a new study suggests.

A phase 2 multicenter trial of about 40 patients with recurrent glioblastoma -- an aggressive brain cancer that typically kills patients within 15 months of diagnosis -- showed that the vaccine safely increased average survival to nearly 48 weeks, compared with about 33 weeks among patients who didn't receive the treatment. The six-month survival rate was 93 percent for the vaccinated group, compared with 68 percent for 86 other glioblastoma patients, who were treated with other therapies.

"We've done a lot of things for this kind of tumor in the last 40 or 50 years, all variations on different chemotherapies that haven't really panned out," said Dr. Jonas Sheehan, director of neuro-oncology at the Penn State Cancer Institute, who was not involved in the study. "What we've known needed to happen for a while now is a revolution -- a totally new way of approaching these tumors. This is an example of a totally new paradigm."

The study is scheduled to be presented Tuesday at the annual meeting of the American Association of Neurological Surgeons (AANS), in Miami.

About a quarter of the 18,500 brain tumors diagnosed each year are glioblastomas, which are more common in men and typically occur between the ages of 50 and 70, according to the AANS. Kennedy died of the malignancy in 2009, 15 months after his diagnosis. Surgery, radiation and chemotherapy are among the standard treatment options.

The vaccine used in the trial, known as HSPPC-96, was created with tumor cells from patients who had undergone surgery to remove as much tumor as possible. The vaccine was then injected into their bodies to induce an immune response against the tumor, said lead investigator Dr. Andrew Parsa, vice chairman of neurological surgery at University of California, San Francisco. Side effects among participants were minimal.

"It's the concept of chronic therapy, to turn this into a chronic disease like hypertension and diabetes," said Parsa, who noted that no drug companies funded the study. "It's the only therapy in the clinical realm that has a reasonable chance of doing this, because we can't give patients chemotherapy [because of toxicity] for unlimited amounts of time."

Parsa said the vaccine's impact, if validated with a randomized study in the near future, could be a "total game-changer."

Added Sheehan: "The hope is that we'll go from a survival of 15 months to a meaningful difference. We're looking to go from 15 months to five years, a quantum leap forward."

Because this study was to be presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.

More information

Visit the American Association of Neurological Surgeons for more on glioblastomas.

SOURCES: Andrew Parsa, M.D., Ph.D., professor and vice chairman, neurological surgery, University of California, San Francisco; Jonas Sheehan, M.D., director, neuro-oncology, Penn State Cancer Institute, Hershey, Pa.; April 17, 2012, presentation, abstract, American Association of Neurological Surgeons, annual meeting, Miami


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Football-related catastrophic brain injuries on the rise
2. Researchers Map Brain Regions Linked to Intelligence
3. Nonsurgical Method to Measure Brain Pressure Shows Promise
4. Dental X-Rays May Be Linked to Benign Brain Tumors
5. Brain Falters Near End of Life, but Games, Puzzles Might Slow Decline
6. Why is traumatic brain injury increasing among the elderly?
7. UCLA Brain Injury Research Center gets NCAA funding for research on sports concussions
8. Epilepsy Leads to More Brain Abnormalities Over Time
9. Study Suggests Vaccine May Help Kids With Brain Cancer
10. Our brains on food: From anorexia to obesity and everything in between
11. Northwestern study compares endovascular brain aneurysm repair devices
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Brain Tumor Vaccine Shows Promise in Early Trial
(Date:10/13/2017)... ... 13, 2017 , ... Ellevate Network, the leading network for professional women, brought ... gender equality at their inaugural Summit in New York City in June. The event ... audience of over 3 million. To watch the Mobilize Women video, click here ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains ... possible to save lost souls in the Philippines. “The Journey: From the Mountains to ... dedicated teacher of the Bible. She has taught all ages and currently teaches a ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, ... a medical article to the newly revamped Cosmetic Town journal section, ... hair transplant procedure known as Follicular Unit Extraction (FUE). , Dr. ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health ... interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), an ... education, today announce a new strategic alliance. , As CPEN’s strategic partner, ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/22/2017)... 2017 AVACEN Medical (AVACEN) announced that its ... helping those with the widespread pain associated with fibromyalgia ... in Essex, England commented, "I ... experiencing no sleep at all, tremendous pain, with every ... recommend [the AVACEN 100] enough, how this has and ...
Breaking Medicine Technology: